#### DF 118 : the powerful one.

#### Contributors

Duncan, Flockhart & Co.

#### **Publication/Creation**

[approximately 1975]

#### **Persistent URL**

https://wellcomecollection.org/works/yrjqwhxf

#### License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection 183 Euston Road London NW1 2BE UK T +44 (0)20 7611 8722 E library@wellcomecollection.org https://wellcomecollection.org



# The powerful one

Because DF 118 is a powerful analgesic it works well in small doses, leaves your patient alert and allows him to go about his everyday tasks normally, without the need for follow-ups until a repeat is necessary.

Transfer a chronic patient to DF118 and notice how dramatically you reduce his analgesic intake. The effective dose, once established, will remain steady and any concomitant therapy is simpler for him to control.

Acute patients, too, benefit from DF118 since

DF

the fully active oral route lessens the need for injections. For patients who cannot swallow tablets Elixir DF 118 offers an alternative form with greater flexibility of dosage.

Low dosage leads to low cost and the basic cost of 28 tablets (an average week's supply) is only 27p.



Each DF 118 tablet contains Dihydrocodeine tartrate BP 30mg. Each 5 ml Elixir DF 118 contains Dihydrocodeine tartrate BP 10mg.

### DF 118 subdues the pain, but not the patient.

Full information is available from DUNCAN, FLOCKHART & CO. LTD., LONDON E2 6LA.


MULTI-CENTRE INTERNATIONAL STUDY SHOWS THAT

## **Beta-blockade reduces cardiac mortality**

An important multi-centre international study<sup>†</sup> has referred to the experience already obtained with propranolol, practolol and sotalol (Beta-Cardone).

It demonstrates an improved prognosis for patients with recent anterior myocardial infarction who were on long-term practolol therapy and concludes that these findings are likely to be applicable to other beta-adrenoreceptor antagonists.

It recommends that because of severe side effects in the long-term use of practolol an alternative beta-blocking agent should be used. Such an agent is Beta-Cardone, the beta-blocker with comparable length of action to practolol.



Beta-Cardone, the pure beta-blocker, has been widely researched and clinically investigated since 1962. It is especially prolonged in its duration of action as evidenced by the above table.

#### Protection for the heart day and night

Beta-Cardone the longer acting beta-blocker